Paola Bordi

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Alessio Cortellini, Rita Chiari, Biagio Ricciuti et al. · Clinical Lung Cancer · 2019 · 179 citations

Life Sciences, Immunology, Oncology +16

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLC

Melissa Bersanelli, Roberta Minari, Paola Bordi et al. · Journal of Thoracic Oncology · 2016 · 166 citations · Full text

Medicine, Medicinal Chemistry, Oncology +15

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

Alessio Cortellini, Massimo Di Maïo, Olga Nigro et al. · Journal for ImmunoTherapy of Cancer · 2021 · 144 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC

Giulia Mazzaschi, Francesco Facchinetti, Gabriele Missale et al. · Lung Cancer · 2018 · 136 citations

Life Sciences, Immunology, Oncology +17

Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Giulia Mazzaschi, Roberta Minari, Alessandra Zecca et al. · Lung Cancer · 2020 · 117 citations

Life Sciences, Immunology, Oncology +17